GPC3 and neoplasm: NK cells target tumor cells sensitized by monoclonal antibodies specific for tumor associated antigens GPC-3 or AFFP on tumor cells by mediating ADCC (Figure 1D) and this would also be a promising therapeutic strategy after activation of NK cells with cytokines such as IL-15 [73,83].